Auf dieser Seite
CBIO Crescent Biopharma, Inc. - Common Stock
NASDAQ · Biotechnology · Auf SEC EDGAR ansehen ↗ Schließen Okt 2, 2026 10-K/10-Q Jul 30, 2026
$14,32
· % der 52-Wochen-Spanne
· über Tiefststand
· zu hoch
$8,7252-Wochen-Tief
$27,4152-Wochen-Hoch
Marktkapitalisierung (MRQ)
$397M
P/E
-29.2
EPS
$-0.59
Umsatz
$11M
Ihre Abzeichen
52W-Spanne
$9–$27
Analystenbewertung
BUY
Kursziel
$31
P/E
-29.2
ROE
-90.0%
Nettogewinnmarge
-1419.6%
Ihre Abzeichenleiste ist leer – heften Sie eine Kennzahl auf dieser Seite an.
CBIO Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$14.32
Marktkapitalisierung (MRQ)
$397M
P/E
-29.2
EPS
$-0.59
Umsatz
$11M
ROE
-90.0%
52W-Spanne
$9–$27
CBIO Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Spanne
Balken
Die Balkengranularität passt sich der ausgewählten Periode an – bewegen Sie den Mauszeiger über das Diagramm, um Eröffnungs-/Höchst-/Tiefst-/Schlusskurse für einen Balken anzuzeigen.
Aktiensplits
| Ex-Datum | Split | Typ |
|---|---|---|
| 16. Juni 2025 | 1-for-100 | Umgekehrt |
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz$11M2016-12-31 → 2025-12-31
EPS$-0.592019-12-31 → 2024-12-31
Freier Cashflow$-72M2016-12-31 → 2025-12-31
Nettogewinnmarge-1419.6%2016-12-31 → 2025-12-31
Bewertung & Kennzahlen
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
| Kennzahl | 5-Jahres-Trend | CBIO | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| P/E | -29.25-Jahres-Durchschnitt ≈-186.2 | ≈-186.2 | · | · | |
| P/S | 36.45-Jahres-Durchschnitt ≈436476.1 | ≈436476.1 | 144.0 | Unterbewertet | |
| K/B (MRQ) | 2.45-Jahres-Durchschnitt ≈235.3 | ≈235.3 | 3.0 | Fairer Wert | |
| Kurs / FCF (TTM) | -5.45-Jahres-Durchschnitt ≈-195.4 | ≈-195.4 | · | · | |
| Kurs / Cashflow (TTM) | -5.55-Jahres-Durchschnitt ≈-195.6 | ≈-195.6 | · | · | |
| Price / Tangible Book (Kurs / Materieller Buchwert) | 1.95-Jahres-Durchschnitt ≈218.3 | ≈218.3 | · | · |
Der Median der Vergleichsgruppe wird pro Kennzahl standardisiert berechnet und stimmt möglicherweise nicht immer mit der für diese Aktie angezeigten TTM/MRQ-Basis überein.
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
| Kennzahl | 5-Jahres-Trend | CBIO | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Operating Margin (Betriebsgewinnmarge) | -1407.5%5-Jahres-Durchschnitt ≈-115708.9% | ≈-115708.9% | -2380.1% | Im Einklang | |
| EBITDA Margin (EBITDA-Marge) | -1407.5%5-Jahres-Durchschnitt ≈-115708.9% | ≈-115708.9% | -2380.1% | Im Einklang | |
| Pretax Margin (Vorgewinnmarge) | -1401.2% | · | -5050.3% | Spitzenklasse | |
| Net Profit Margin (Nettogewinnmarge) | -1419.6%5-Jahres-Durchschnitt ≈-109533.6% | ≈-109533.6% | -2240.9% | Im Einklang | |
| ROA | -111.6%5-Jahres-Durchschnitt ≈-87.8% | ≈-87.8% | -40.8% | Schwach | |
| ROE | -90.0%5-Jahres-Durchschnitt ≈-447.8% | ≈-447.8% | -52.8% | Schwach | |
| ROIC | -76.2% | · | -39.0% | Schwach |
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
| Kennzahl | 5-Jahres-Trend | CBIO | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Liquiditätsgrad (MRQ) | 9.75-Jahres-Durchschnitt ≈5.7 | ≈5.7 | 12.9 | Geringe Liquidität | |
| Quick Ratio | 6.45-Jahres-Durchschnitt ≈5.5 | ≈5.5 | 10.5 | Im Einklang |
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
| Kennzahl | 5-Jahres-Trend | CBIO | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Revenue YoY (Umsatz YoY) | -86.7%5-Jahres-Durchschnitt ≈-89.6% | ≈-89.6% | · | · | |
| Revenue CAGR 3Y (Umsatz CAGR 3J) | 424.9% | · | · | · | |
| Revenue CAGR 5Y (Umsatz CAGR 5J) | 1.3% | · | · | · |
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
| Kennzahl | 5-Jahres-Trend | CBIO | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Asset Turnover (Umsatz / Vermögenswerte) | 0.15-Jahres-Durchschnitt ≈0.0 | ≈0.0 | 0.0 | Spitzenklasse | |
| Receivables Turnover (Forderungsumschlag) | 1.2 | · | · | · | |
| Revenue / Employee (Umsatz / Mitarbeiter) | ≈$157.2K | · | · | · |
Wert · ≈ 5-Jahres-Durchschnitt · Branchenmedian · Urteil relativ zum Median
Dividenden Rendite, Ausschüttungsquote, Dividendenhistorie, 5-Jahres-CAGR
Annualisierte Auszahlung≈$96.00
| Ex-Datum | Betrag | Währung | Rendite |
|---|---|---|---|
| Jan 13, 2023 | $24,00 | USD | ≈55.3% |
| Sep 21, 2022 | $143,00 | USD | ≈223.4% |
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
-0.05%
Nächster Bericht
Nov 04, 2026
| Zeitraum | Bericht | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|---|
| 30. Juni 2026 | $-0.74 | $-0.81 | 8.7% | |
| 31. März 2026 | $-0.70 | $-0.97 | 27.5% | |
| 31. Dezember 2025 | $-0.54 | $-2.57 | 79.0% | |
| 30. September 2025 | $-1.27 | $-2.02 | 37.2% | |
| 30. Juni 2025 | $-4.93 | $-1.80 | -174.2% | |
| 31. März 2025 | $-4.00 | $-5.10 | 21.6% |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11M | · | $10.0K | $75.0K | $1M | $10M | · | · | · | $18.5K | $20M | $15M | |
| R&D Expense | $138M | $14M | $20M | $28M | $47M | $45M | $47M | $40M | $24M | $23M | $25M | $20M | |
| SG&A Expense | $25M | $18M | $19M | $19M | $17M | $17M | $14M | $11M | $10M | $9M | $8M | $7M | |
| Operating Expenses | $163M | $40M | $39M | $47M | $65M | $62M | $61M | $52M | $34M | $32M | $33M | $26M | |
| Operating Income | $-153M | $-40M | $-39M | $-47M | $-63M | $-52M | $-61M | $-52M | $-34M | $-32M | $-13M | $-11M | |
| Other Non-op | · | $2M | $2M | · | · | · | · | · | $651.2K | $103.6K | $15.3K | $18.2K | |
| Pretax Income | $-152M | · | · | · | · | · | · | · | · | · | · | · | |
| Income Tax | $2M | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income | $-154M | $-38M | $-37M | $-47M | $-63M | $-51M | $-58M | $-48M | $-33M | $-32M | $-13M | $-11M | |
| EPS (Basic) | · | $-0.59 | $-0.58 | $-0.89 | $-1.23 | $-1.12 | $-1.34 | · | · | · | · | $-0.60 | |
| EPS (Diluted) | · | $-0.59 | $-0.58 | $-0.89 | $-1.23 | $-1.12 | $-1.34 | · | · | · | · | $-0.60 | |
| Shares (Basic) | · | 64,477,249 | 63,342,465 | 52,531,173 | 51,453,204 | 45,721,139 | 43,254,782 | · | · | · | · | 18,452,252 | |
| Shares (Diluted) | · | 64,477,249 | 63,342,465 | 52,531,173 | 51,453,204 | 45,721,139 | 43,254,782 | · | · | · | · | 18,452,252 | |
| EBITDA | $-153M | $-40M | $-39M | $-47M | $-63M | $-52M | $-61M | $-52M | $-34M | $-32M | $-13M | $-11M |
Bilanz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $213M | $35M | $42M | $48M | $90M | $137M | $158M | $210M | $124M | $40M | $47M | $55M | |
| Receivables | $18M | $0 | · | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $5M | $38.0K | $2M | $3M | $533.8K | $1M | $4M | $2M | $3M | $478.5K | $441.8K | $916.2K | |
| Other Current Assets | $5M | $38.0K | · | · | · | · | · | · | · | · | · | · | |
| Current Assets | $237M | $35M | $44M | $51M | $91M | $138M | $163M | $212M | $127M | $41M | $47M | $56M | |
| PP&E (Net) | $846.0K | $0 | · | $242.4K | $368.8K | $620.7K | $822.9K | $957.2K | $1M | $1M | $521.4K | $452.3K | |
| PP&E (Gross) | · | · | · | $3M | $3M | $3M | $3M | $3M | $2M | $2M | $1M | $1M | |
| Accum. Depreciation | · | · | · | $2M | $2M | $2M | $2M | $2M | $1M | $1M | $902.1K | $905.5K | |
| Other Non-current Assets | $1M | $813.0K | · | · | · | · | · | · | · | · | · | · | |
| Total Assets | $240M | $36M | $45M | $52M | $94M | $143M | $168M | $215M | $129M | $42M | $48M | $57M | |
| Accounts Payable | · | $329.3K | $868.1K | $970.2K | $2M | $2M | $1M | $3M | $3M | $2M | $564.2K | $874.0K | |
| Accrued Liabilities | $16M | $2M | $5M | $7M | $9M | $9M | $9M | $6M | $4M | $3M | $6M | $5M | |
| Current Liabilities | $36M | $10M | $7M | $9M | $12M | $12M | $11M | $9M | $8M | $6M | $8M | $6M | |
| Capital Leases | $1M | $0 | $66.8K | · | $918.6K | $2M | $3M | · | · | · | · | · | |
| Total Liabilities | $37M | $47M | $7M | $9M | $13M | $15M | $14M | $9M | $9M | $7M | $8M | $6M | |
| Common Stock | $28.0K | $1.0K | $64.4K | $54.4K | $52.3K | $49.0K | $43.5K | $43.2K | $34.4K | $23.2K | $19.0K | $18.9K | |
| Paid-in Capital | $371M | $2M | $495M | $462M | $454M | $438M | $413M | $406M | $272M | $154M | $128M | $125M | |
| Retained Earnings | $-172M | $-18M | $-456M | $-420M | $-373M | $-309M | $-258M | $-201M | $-152M | $-119M | $-87M | $-74M | |
| Stockholders' Equity | $203M | $-15M | $38M | $43M | $82M | $128M | $154M | $205M | $120M | $35M | $40M | $51M | |
| Liabilities + Equity | $240M | $36M | $45M | $52M | $94M | $143M | $168M | $215M | $129M | $42M | $48M | $57M | |
| Shares Outstanding | 27,556,767 | 1,018,604 | 64,393,744 | 54,377,798 | 52,313,894 | 49,017,622 | 43,466,933 | 43,160,751 | 34,359,799 | 23,250,023 | 19,050,204 | 18,939,838 |
Cashflow
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $13M | $5M | $4M | $4M | $6M | $7M | $6M | $5M | $4M | $3M | $2M | $2M | |
| Deferred Tax | $0 | · | · | · | · | · | · | · | · | · | · | · | |
| Restructuring | · | $7M | · | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-72M | $-31M | $-35M | $-46M | $-57M | $-39M | $-52M | $-43M | $-30M | $-30M | $-8M | $-4M | |
| CapEx | $919.0K | $10.0K | $21.4K | $84.2K | $14.9K | $68.5K | $144.9K | $125.6K | $294.1K | $704.2K | $268.6K | $212.6K | |
| Investing Cash Flow | $-73M | $20.0K | $-21.4K | $-84.2K | $-14.9K | $-68.5K | $-144.9K | $-125.6K | $-294.1K | $-704.2K | $-268.6K | · | |
| Stock Issued | $0 | · | $29M | $4M | $11M | $18M | · | $128M | $114M | $24M | · | $57M | |
| Net Stock Activity | $0 | · | $29M | $4M | $11M | $18M | · | $128M | $114M | $24M | · | $57M | |
| Financing Cash Flow | $323M | $5.4K | $29M | $4M | $11M | $18M | $412.9K | $129M | $114M | $24M | $114.1K | · | |
| Net Change in Cash | $179M | $-31M | $-6M | $-42M | $-47M | $-21M | $-52M | $86M | $84M | $-7M | $-8M | $53M | |
| Free Cash Flow | $-72M | $-31M | $-35M | $-47M | $-58M | $-39M | $-52M | $-43M | $-30M | $-30M | $-9M | $-4M |
Rentabilität
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -1407.5% | · | -392752.9% | -63204.4% | -5470.7% | -506.8% | · | · | · | -172505.3% | -63.7% | -74.1% | |
| Net Margin | -1419.6% | · | -368994.2% | -62251.7% | -5469.0% | -502.1% | · | · | · | -171945.1% | -63.6% | -74.0% | |
| Pretax Margin | -1401.2% | · | · | · | · | · | · | · | · | · | · | · | |
| EBITDA Margin | -1407.5% | · | -392752.9% | -63204.4% | -5470.7% | -506.8% | · | · | · | -172505.3% | -63.7% | -74.1% | |
| ROA | -111.6% | -134.3% | -76.0% | -63.9% | -53.5% | -32.8% | -30.2% | -28.1% | -38.9% | -70.0% | -24.2% | -35.6% | |
| ROE | -90.0% | -1888.5% | -86.9% | -102.6% | -71.2% | -38.3% | -36.0% | -22.8% | -42.9% | -84.0% | -28.0% | -41.4% | |
| ROIC | -76.2% | · | · | · | · | · | · | · | · | · | · | · |
Liquidität & Solvenz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.6 | 1.9 | 6.4 | 5.7 | 7.7 | 11.1 | 14.8 | 24.2 | 15.6 | 6.4 | 6.1 | 8.7 | |
| Quick Ratio | 6.4 | 1.9 | 6.1 | 5.4 | 7.6 | 11.0 | 14.4 | 24.0 | 15.2 | 6.3 | 6.0 | 8.5 |
Effizienz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | · | 0.0 | 0.0 | 0.0 | 0.1 | · | · | · | 0.0 | 0.4 | 0.5 | |
| Receivables Turnover | 1.2 | · | · | · | · | · | · | · | · | · | · | · |
Pro Aktie
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $7.37 | $0.08 | $0.60 | $0.79 | $1.56 | $2.62 | $3.55 | $4.76 | $3.48 | $1.52 | $2.12 | $2.68 | |
| Revenue / Share | · | · | $0.00 | $0.00 | $0.02 | · | · | · | · | · | · | $0.81 | |
| Cash Flow / Share | · | $-0.48 | $-0.55 | $-0.88 | $-1.12 | · | · | · | · | · | · | $-0.23 | |
| Cash / Share | $7.74 | $0.17 | $0.65 | $0.88 | $1.73 | $2.80 | $3.64 | $4.86 | $3.61 | $1.72 | $2.46 | $2.91 | |
| EPS (TTM) | $-0.49 | $-0.59 | $-0.58 | $-0.89 | $-1.23 | $-1.12 | $-1.34 | $-0.75 | $-0.75 | $-0.75 | $-0.71 | $-0.60 |
Wachstumsraten
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | · | · | -86.7% | -93.5% | -88.6% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 424.9% | · | -90.0% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 1.3% | · | · | · | · | · | · | · | · | · | · | · |
Bewertung (TTM)
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $11M | · | $10.0K | $75.0K | $1M | $10M | · | · | · | $18.5K | $20M | $15M | |
| Net Income TTM | $-154M | $-38M | $-37M | $-47M | $-63M | $-51M | $-58M | $-48M | $-33M | $-32M | $-13M | $-11M | |
| Market Cap | $327M | $1.61B | $15.20B | $16.48B | $7.53B | $18.43B | $22.99B | $40.87B | $57.69B | $14.18B | $10.90B | $13.64B | |
| P/E | -24.2 | -42.4 | -406.9 | -340.4 | -117.1 | -335.7 | -394.8 | -1262.7 | -2238.7 | -813.3 | -805.6 | -1200.0 | |
| P/S | 30.1 | · | 1519692.4 | 219686.3 | 6495.4 | 1813.5 | · | · | · | 766622.4 | 542.9 | 907.5 | |
| P/B | 1.6 | 303.4 | 395.6 | 383.8 | 92.3 | 143.7 | 149.1 | 198.9 | 481.9 | 401.8 | 269.2 | 268.4 | |
| P / Tangible Book | 1.6 | · | 395.6 | 383.8 | 92.3 | 143.7 | · | · | · | · | · | · | |
| P / Cash Flow | -4.6 | -51.8 | -435.7 | -354.7 | -131.0 | -469.7 | -442.3 | -943.3 | -1938.0 | -477.0 | -1322.1 | -3185.0 | |
| P / FCF | -4.5 | -51.8 | -435.4 | -354.0 | -131.0 | -468.8 | -441.1 | -940.5 | -1919.0 | -466.0 | -1280.4 | -3034.3 | |
| Earnings Yield | -4.1% | -2.4% | -0.25% | -0.29% | -0.85% | -0.30% | -0.25% | -0.08% | -0.04% | -0.12% | -0.12% | -0.08% |
Gewinn- und Verlustrechnung
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $1M | · | · | $0 | $0 | · | · | · | · | · | · | · | · | $0 | · | |
| R&D Expense | $19M | $18M | $106M | $20M | $12M | $11M | $233.2K | $2M | $6M | $6M | $5M | $5M | $4M | $5M | $6M | $5M | |
| SG&A Expense | $9M | $8M | $9M | $6M | $9M | $4M | $5M | $4M | $4M | $5M | $4M | $5M | $5M | $6M | $5M | $4M | |
| Operating Expenses | $28M | $26M | $114M | $26M | $21M | $14M | $7M | $11M | $10M | $11M | $10M | $10M | $9M | $11M | $11M | $9M | |
| Operating Income | $-26M | $-25M | $-103M | $-26M | $-21M | $-14M | $-7M | $-11M | $-10M | $-11M | $-10M | $-10M | $-9M | $-11M | $-11M | $-9M | |
| Other Non-op | $2M | $1M | · | $1M | $-760.0K | $-924.0K | $110.1K | $1M | · | · | $512.2K | $611.0K | · | · | · | · | |
| Income Tax | $0 | $0 | $2M | $0 | $0 | $0 | · | · | · | · | · | · | · | · | · | · | |
| Net Income | $-25M | $-23M | $-23M | $-25M | $-22M | $-15M | $-7M | $-10M | $-10M | $-11M | $-9M | $-9M | $-8M | $-10M | $-10M | $-9M | |
| EPS (Basic) | · | · | · | · | · | $-0.04 | $-0.11 | $-0.15 | $-0.16 | $-0.17 | $-0.14 | $-0.14 | $-0.13 | $-0.17 | $-0.20 | $-0.16 | |
| EPS (Diluted) | · | · | · | · | · | · | $-0.24 | $-0.15 | $-0.16 | $-0.04 | $-0.14 | $-0.14 | $-0.13 | $-0.17 | $-0.20 | $-0.16 | |
| Shares (Basic) | · | · | · | · | · | 64,522,257 | · | 64,483,958 | 64,483,848 | 64,457,233 | · | 64,349,709 | 64,276,184 | 60,350,127 | · | 52,423,944 | |
| Shares (Diluted) | · | · | · | · | · | · | · | 64,483,958 | 64,483,848 | 64,522,257 | · | 64,349,709 | 64,276,184 | 64,457,233 | · | 52,423,944 | |
| EBITDA | $-26M | · | · | $-26M | $-21M | · | · | $-11M | $-10M | $-11M | · | $-10M | $-9M | $-11M | · | $-9M |
Bilanz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $172M | $189M | $213M | $133M | $153M | $6M | $11M | $14M | $22M | $31M | $42M | $49M | $58M | $65M | $48M | $52M | |
| Receivables | $0 | $0 | $18M | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $7M | $6M | $5M | $1M | $2M | $378.0K | $371.3K | $1M | $1M | $2M | $2M | $3M | $2M | $3M | $3M | $2M | |
| Other Current Assets | $7M | $6M | $5M | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Current Assets | $179M | $196M | $237M | $135M | $154M | $6M | $11M | $16M | $24M | $33M | $44M | $52M | $60M | $68M | $51M | $54M | |
| PP&E (Net) | $876.0K | $929.0K | $846.0K | $782.0K | $193.0K | · | · | · | · | · | · | $133.0K | $167.9K | $200.7K | · | $288.1K | |
| PP&E (Gross) | · | · | · | · | · | · | · | · | · | · | · | $3M | $3M | $3M | · | $3M | |
| Accum. Depreciation | · | · | · | · | · | · | · | · | · | · | · | $3M | $2M | $2M | · | $2M | |
| Other Non-current Assets | $1M | $1M | $1M | $1M | $1M | · | · | · | · | · | · | · | · | · | · | · | |
| Total Assets | $183M | $199M | $240M | $138M | $157M | $6M | $11M | $16M | $24M | $34M | $45M | $53M | $62M | $69M | $52M | $56M | |
| Accounts Payable | · | · | · | · | · | $104.7K | $329.3K | $581.8K | $950.8K | $755.5K | $868.1K | $329.9K | $241.5K | $480.2K | $970.2K | $852.1K | |
| Accrued Liabilities | $7M | $4M | $16M | $9M | $8M | $3M | $5M | $3M | $3M | $4M | $5M | $5M | $6M | $6M | $7M | $6M | |
| Current Liabilities | $19M | $14M | $36M | $20M | $17M | $3M | $6M | $4M | $4M | $5M | $7M | $6M | $7M | $7M | $9M | $8M | |
| Capital Leases | $966.0K | $1M | $1M | $1M | $1M | · | · | · | · | · | $66.8K | $262.1K | $448.8K | · | · | $95.6K | |
| Total Liabilities | $20M | $15M | $37M | $22M | $18M | $3M | $6M | $4M | $4M | $5M | $7M | $7M | $7M | $7M | $9M | $8M | |
| Common Stock | $28.0K | $28.0K | $28.0K | $14.0K | $14.0K | $64.5K | $64.5K | $64.5K | $64.5K | $64.5K | $64.4K | $64.4K | $64.3K | $64.2K | $54.4K | $52.4K | |
| Paid-in Capital | $379M | $375M | $371M | $192M | $190M | $500M | $500M | $498M | $497M | $496M | $495M | $494M | $493M | $492M | $462M | $457M | |
| Retained Earnings | $-220M | $-195M | $-172M | $-79M | $-55M | $-497M | $-494M | $-487M | $-477M | $-467M | $-456M | $-447M | $-438M | $-430M | $-420M | $-409M | |
| Stockholders' Equity | $163M | $184M | $203M | $117M | $139M | $3M | $5M | $11M | $20M | $29M | $38M | $47M | $55M | $62M | $43M | $48M | |
| Liabilities + Equity | $183M | $199M | $240M | $138M | $157M | $6M | $11M | $16M | $24M | $34M | $45M | $53M | $62M | $69M | $52M | $56M | |
| Shares Outstanding | 27,756,044 | 27,571,935 | 27,556,767 | 13,892,516 | 13,892,562 | 64,532,091 | 64,483,958 | 64,483,958 | 64,483,958 | 64,450,835 | 64,393,744 | 64,368,843 | 64,313,333 | 64,245,224 | 54,377,798 | 52,423,944 |
Cashflow
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $4M | $4M | $5M | $2M | $6M | $1M | $1M | $1M | $1M | $1M | $908.4K | $887.8K | $858.1K | $870.2K | $899.2K | $914.0K | |
| Restructuring | · | · | · | · | · | · | · | $5M | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-19M | $-9M | $-27M | $-18M | $-22M | $-11M | $-4M | $-8M | $-9M | $-11M | $-8M | $-9M | $-7M | $-12M | $-8M | $-9M | |
| CapEx | $13.0K | $147.0K | $193.0K | $586.0K | $140.0K | $0 | $0 | $0 | $2.5K | $7.4K | $801 | $7.9K | $10.5K | $2.2K | $1 | $2.5K | |
| Investing Cash Flow | $2M | $-8M | $-72M | $-586.0K | $-140.0K | $0 | $30.0K | $0 | $-2.5K | $-7.4K | $-801 | $-7.9K | $-10.5K | $-2.2K | $-1 | $-2.5K | |
| Stock Issued | · | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | $29M | · | · | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | · | · | · | · | $29M | · | · | |
| Financing Cash Flow | $136.0K | $-7M | $179M | $-1M | $147M | $-1M | $0 | $0 | $500 | $4.9K | $999 | $61.6K | $20.1K | $29M | · | · | |
| Net Change in Cash | $-18M | $-24M | $80M | $-19M | $123M | $-12M | $-4M | $-8M | $-9M | $-11M | $-8M | $-9M | $-7M | $17M | $-4M | $-9M | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | $-11M | · | · | · | $-12M | · | · |
Rentabilität
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROA | -14.6% | · | · | -32.0% | -24.0% | · | · | · | -23.4% | -20.8% | · | -16.9% | -13.0% | -13.8% | · | -10.4% | |
| ROE | -16.4% | · | · | -38.4% | -27.4% | · | · | · | -27.0% | -23.6% | · | -19.4% | -14.9% | -15.9% | · | -11.8% |
Liquidität & Solvenz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 9.7 | · | · | 6.6 | 9.2 | · | · | · | 5.5 | 6.3 | · | 8.1 | 9.2 | 10.1 | · | 6.9 | |
| Quick Ratio | 9.3 | · | · | 6.6 | 9.1 | · | · | · | 5.1 | 5.9 | · | 7.7 | 8.8 | 9.6 | · | 6.7 |
Effizienz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Receivables Turnover | 0.0 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
Pro Aktie
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $5.88 | · | · | $8.40 | $10.02 | · | · | · | $0.31 | $0.45 | · | $0.72 | $0.85 | $0.97 | · | $0.92 | |
| Cash Flow / Share | · | · | · | · | · | · | · | · | · | $-0.16 | · | · | · | $-0.19 | · | · | |
| Cash / Share | $6.18 | · | · | $9.59 | $10.99 | · | · | · | $0.35 | $0.49 | · | $0.77 | $0.90 | $1.01 | · | $0.98 | |
| EPS (TTM) | $-0.59 | $-0.49 | · | $-0.59 | $-0.59 | $-0.59 | · | $-0.49 | $-0.48 | $-0.45 | · | $-0.64 | $-0.66 | $-0.78 | · | $-1.02 |
Bewertung (TTM)
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-96M | $-93M | · | $-69M | $-54M | $-42M | · | $-40M | $-39M | $-37M | · | $-38M | $-37M | $-42M | · | $-54M | |
| Market Cap | $500M | · | · | $165M | $224M | · | · | · | $1.81B | $19.34B | · | $9.66B | $11.19B | $8.09B | · | $2.88B | |
| P/E | -30.5 | -37.5 | · | -20.2 | -27.4 | -35.6 | · | -34.7 | -58.3 | -666.7 | · | -234.4 | -263.6 | -161.5 | · | -53.9 | |
| P/B | 3.1 | · | · | 1.4 | 1.6 | · | · | · | 90.0 | 668.8 | · | 207.4 | 204.2 | 130.2 | · | 59.9 | |
| P / Tangible Book | 3.1 | 2.8 | · | 1.4 | 1.6 | 401.5 | · | 96.4 | 90.0 | 668.8 | · | 207.4 | 204.2 | 130.2 | · | 59.9 | |
| P / Cash Flow | · | · | · | · | · | · | · | · | · | -1839.9 | · | · | · | -697.4 | · | · | |
| Earnings Yield | -3.3% | -2.7% | · | -5.0% | -3.7% | -2.8% | · | -2.9% | -1.7% | -0.15% | · | -0.43% | -0.38% | -0.62% | · | -1.8% |
Aktuellster Zeitraum links · fehlende Werte werden als · angezeigt
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Umsatz | $11M | · | $10.0K | $75.0K | $1M |
| Betriebsgewinnmarge % | -1407.5% | · | -392752.9% | -63204.4% | -5470.7% |
| Nettoergebnis | $-154M | $-38M | $-37M | $-47M | $-63M |
| Verwässerte EPS | · | $-0.59 | $-0.58 | $-0.89 | $-1.23 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Liquiditätsgrad | 6.6 | 1.9 | 6.4 | 5.7 | 7.7 |
| Quick Ratio | 6.4 | 1.9 | 6.1 | 5.4 | 7.6 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Freier Cashflow | $-72M | $-31M | $-35M | $-47M | $-58M |
Institutionelle Eigentümer (13F) 82 Einreicher · $526.1M gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Inhaber
82
Gehaltener Wert
$526.1M
Neue Positionen
32
Geschlossene Positionen
12
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 32 (+15 vs. Vorquartal) | 12 (+2 vs. Vorquartal) | 17 (0 vs. Vorquartal) | 14 (+6 vs. Vorquartal) | +4.0M |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| FMR LLC | $74.403.252 | 4.133.514 | 14,14% | Aktien |
| BVF INC/IL | $49.477.734 | 2.748.763 | 9,40% | Aktien |
| Fairmount Funds Management LLC | $49.461.588 | 2.747.866 | 9,40% | Aktien |
| Venrock Adviser, LLC | $38.404.368 | 2.133.576 | 7,30% | Aktien |
| Logos Global Management LP | $34.200.000 | 1.900.000 | 6,50% | Aktien |
| FCPM III SERVICES B.V. | $30.201.336 | 1.677.852 | 5,74% | Aktien |
| Balyasny Asset Management L.P. | $29.932.506 | 1.662.917 | 5,69% | Aktien |
| Vestal Point Capital, LP | $29.340.000 | 1.630.000 | 5,58% | Aktien |
| Opaleye Management Inc. | $23.748.318 | 1.319.351 | 4,51% | Aktien |
| BlackRock, Inc. | $22.891.716 | 1.271.762 | 4,35% | Aktien |
| TANG CAPITAL MANAGEMENT LLC | $20.880.000 | 1.160.000 | 3,97% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $13.819.590 | 767.755 | 2,63% | Aktien |
| MILLENNIUM MANAGEMENT LLC | $7.269.462 | 403.859 | 1,38% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $6.923.843 | 384.576 | 1,32% | Aktien |
| JENNISON ASSOCIATES LLC | $6.813.126 | 378.507 | 1,30% | Aktien |
| RTW INVESTMENTS, LP | $6.711.408 | 372.856 | 1,28% | Aktien |
| NEXTBio Capital Management LP | $6.711.408 | 372.856 | 1,28% | Aktien |
| VANGUARD GROUP INC | $6.612.021 | 557.506 | 1,26% | Aktien |
| Remedium Capital Partners, LLC | $6.502.500 | 361.250 | 1,24% | Aktien |
| STATE STREET CORP | $5.680.566 | 315.587 | 1,08% | Aktien |
| AMERIPRISE FINANCIAL INC | $5.446.224 | 302.568 | 1,04% | Aktien |
| Point72 Asset Management, L.P. | $5.400.000 | 300.000 | 1,03% | Aktien |
| MARSHALL WACE, LLP | $3.857.400 | 214.300 | 0,73% | Aktien |
| PERCEPTIVE ADVISORS LLC | $3.724.956 | 206.942 | 0,71% | Aktien |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $3.398.454 | 188.803 | 0,65% | Aktien |
| TWO SIGMA INVESTMENTS, LP | $3.363.732 | 186.874 | 0,64% | Aktien |
| STEMPOINT CAPITAL LP | $3.282.876 | 182.382 | 0,62% | Aktien |
| UBS Group AG | $3.153.276 | 175.182 | 0,60% | Aktien |
| NORTHERN TRUST CORP | $2.498.004 | 138.778 | 0,47% | Aktien |
| Exome Asset Management LLC | $2.299.842 | 127.769 | 0,44% | Aktien |
| SECTORAL ASSET MANAGEMENT INC | $2.183.400 | 121.300 | 0,42% | Aktien |
| Woodline Partners LP | $1.700.784 | 94.488 | 0,32% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $1.354.050 | 75.225 | 0,26% | Aktien |
| Burkehill Global Management, LP | $1.332.000 | 74.000 | 0,25% | Aktien |
| Blackstone Inc. | $1.127.646 | 62.647 | 0,21% | Aktien |
| SILVERARC CAPITAL MANAGEMENT, LLC | $1.063.872 | 59.104 | 0,20% | Aktien |
| Y-Intercept (Hong Kong) Ltd | $914.832 | 50.824 | 0,17% | Aktien |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $904.644 | 50.258 | 0,17% | Aktien |
| Nuveen, LLC | $857.322 | 47.629 | 0,16% | Aktien |
| Bank of New York Mellon Corp | $824.004 | 45.778 | 0,16% | Aktien |
| Stonepine Capital Management, LLC | $720.000 | 40.000 | 0,14% | Aktien |
| BANK OF AMERICA CORP /DE/ | $464.778 | 25.821 | 0,09% | Aktien |
| RHUMBLINE ADVISERS | $458.766 | 25.487 | 0,09% | Aktien |
| MOORE CAPITAL MANAGEMENT, LP | $450.000 | 25.000 | 0,09% | Aktien |
| Squarepoint Ops LLC | $434.988 | 24.166 | 0,08% | Aktien |
| AMERICAN CENTURY COMPANIES INC | $410.490 | 22.805 | 0,08% | Aktien |
| TWO SIGMA ADVISERS, LP | $385.450 | 32.500 | 0,07% | Aktien |
| WELLS FARGO & COMPANY/MN | $354.600 | 19.700 | 0,07% | Aktien |
| ADAR1 Capital Management, LLC | $328.950 | 18.275 | 0,06% | Aktien |
| Virtus Investment Advisers, LLC | $328.644 | 18.258 | 0,06% | Aktien |
Aktivisten & 5%+-Eigentümer 4 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Peter Harwin, Tomas Kiselak ×3 Einreichungen | 20. Juli 2026 | 16,52% | Änderung | Passive Anlage | SEC |
| Adage Capital Management, L.P., Robert Atchinson, Phillip Gross ×2 Einreichungen | 20. Juni 2025 | 0,37% | Änderung | · | SEC |
| 8. Mai 2024 | · | Erste Einreichung | · | SEC | |
| New Enterprise Associates 10, Limited Partnership, NEA Partners 10, Limited Partnership, New Enterprise Associates 13, L.P., NEA Partners 13, L.P., NEA 13 GP, LTD, Anthony A. Florence, Jr, Mohamad H. Makhzoumi, Scott D. Sandell ×4 Einreichungen | 29. Februar 2024 | · | Erste Einreichung | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Unternehmensinsider 34 Insider · 16 Führungskräfte · 18 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Joshua T Brumm | Chief Executive Officer | 18. September 2026 S | 271.765 | 0 | 3 | $-920.842 |
| Harout Semerjian | Chief Executive Officer | 12. Januar 2024 A | 25.000 | 0 | 0 | $0 |
| Richard William Scalzo | Chief Financial Officer | 16. September 2026 S | 19.730 | 0 | 2 | $-30.172 |
| Brian M. Hahn | SVP Finance, CFO | 18. Juni 2024 P | 70.643 | 0 | 0 | $0 |
| Jonathan Mcneill | President and COO | 18. September 2026 S | 134.588 | 0 | 3 | $-446.912 |
| Jan Pinkas | Chief Scientific Officer | 16. September 2026 S | 21.581 | 0 | 2 | $-34.949 |
| Barbara Harlin Bispham | General Counsel and Corporate Secretary. | 16. September 2026 S | 18.710 | 0 | 2 | $-33.010 |
| Ellie Eunkyung Im | Chief Medical Officer | 16. September 2026 S | 21.446 | 0 | 2 | $-33.082 |
| Ryan Lynch | Treasurer, Senior Vice President of Finance and Chief Accounting Officer. | 16. September 2026 S | 13.631 | 0 | 2 | $-12.661 |
| Christopher Grant Doughty | Chief Business Officer | 15. Dezember 2025 A | 62.194 | 0 | 0 | $0 |
| Edwin Rock | Chief Medical Officer | 21. Juni 2024 P | 680.403 | 0 | 0 | $0 |
| Bruce S Johnson | SVP & Chief Commercial Officer | 12. Januar 2024 A | 138.980 | 0 | 0 | $0 |
| Chinmaya Rath | SVP and Chief Business Officer | 12. Januar 2024 A | · | 0 | 0 | $0 |
| Armand Girard | SVP, Chief Business Officer | 11. November 2022 P | 29.161 | 0 | 0 | $0 |
| John L. Magnani | SVP of Research, CSO | 11. November 2022 P | 366.078 | 0 | 0 | $0 |
| Helen M. Thackray | SVP Clinical Development, CMO | 20. Januar 2021 A | 183.115 | 0 | 0 | $0 |
| Alexandra Balcom | Direktor | 2. Juni 2026 A | · | 0 | 0 | $0 |
| Susan Moran | Direktor | 2. Juni 2026 A | · | 0 | 0 | $0 |
| Jonathan Violin | Direktor | 2. Juni 2026 A | · | 0 | 0 | $0 |
| David Charles Lubner | Direktor | 2. Juni 2026 A | · | 0 | 0 | $0 |
| Rachel K. King | Direktor | 1. Mai 2024 A | 515.194 | 0 | 0 | $0 |
| Scott Koenig | Direktor | 1. Mai 2024 A | 36.750 | 0 | 0 | $0 |
| Scott Thomas Jackson | Direktor | 1. Mai 2024 A | 5.250 | 0 | 0 | $0 |
| Mark Alan Goldberg | Direktor | 1. Mai 2024 A | 24.828 | 0 | 0 | $0 |
| Timothy R Pearson | Direktor | 1. Mai 2024 A | 24.650 | 0 | 0 | $0 |
| Patricia S Andrews | Direktor | 1. Mai 2024 A | 58.608 | 0 | 0 | $0 |
| JUNIUS DANIEL M | Direktor | 1. Mai 2024 A | 98.459 | 0 | 0 | $0 |
| James M Barrett | Direktor | 18. Mai 2018 A | 4.995.664 | 0 | 0 | $0 |
| John J. Baldwin | Direktor | 29. Juni 2016 M | 1.210 | 0 | 0 | $0 |
| Franklin H Top JR | Direktor | 17. Mai 2016 A | 12.294 | 0 | 0 | $0 |
| Michael A Henos | Direktor | 15. Juli 2015 A | 469.454 | 0 | 0 | $0 |
| William M. Gust | Direktor | 15. Januar 2014 C | 409.947 | 0 | 0 | $0 |
| Scott D. Sandell | 10%-Eigentümer | 26. Januar 2023 S | 2.237.196 | 0 | 0 | $0 |
| Peter J Barris | 10%-Eigentümer | 10. Mai 2018 X | 4.995.664 | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
ETF-Besitz Gehalten von 10 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| IWC · iShares Trust | 0,10% | 72.879 SH | 11. September 2026 | Täglich |
| IWO · iShares Trust | 0,03% | 202.796 SH | 11. September 2026 | Täglich |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,02% | 23.282 SH | 19. August 2026 | Täglich |
| IWM · iShares Trust | 0,01% | 544.047 SH | 11. September 2026 | Täglich |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,01% | 124.281 SH | 19. August 2026 | Täglich |
| RSSL · Global X Funds | 0,01% | 10.277 NS | 31. Juli 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,00% | 83.801 SH | 19. August 2026 | Täglich |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 661.946 SH | 19. August 2026 | Täglich |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 1.832 SH | 19. August 2026 | Täglich |
| VHT · VANGUARD WORLD FUND | 0,00% | 39.408 SH | 19. August 2026 | Täglich |
CBIO Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
Bewertung · 15 Analysten
KAUF
Median-Ziel
$28.00
+95,5%
6 40,0%
Starker Kauf
7 46,7%
Kauf
2 13,3%
Halten
0 0,0%
Verkauf
0 0,0%
Starker Verkauf
12-Monats-Kursziel
5 Analysten · 2026-09-30Mittelwert-Ziel $30.60 +113,7%
← Unter allen Zielen
Aktueller Preis $14.32
Tief$27.00
Mittelwert$30.60
Hoch$35.00
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
FY-Basis, Kurse zum Schlusskurs am Ende des letzten Geschäftsjahres jedes Unternehmens.
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| CBIO | $327M | -24.2 | -86.7% | -1419.6% | -90.0% | · |
| ALT | $400M | -3.6 | 105.0% | -214861.0% | -45.6% | · |
| ALLO | $314M | -1.6 | -76.8% | · | -59.9% | · |
| MPLT | $773M | -0.9 | · | · | -151.1% | · |
| MNPR | · | · | · | · | · | · |
| NGNE | $319M | -4.9 | · | · | -33.6% | · |
| ZURA | · | · | · | · | · | · |
| CAPR | $1.66B | -12.8 | -11.6% | · | -51.1% | · |
| PROK | · | · | 1075.0% | -7725.2% | 6.9% | · |
| PBYI | $300M | 9.8 | -0.91% | 13.6% | 26.5% | · |
| RGNX | $733M | -3.8 | 104.5% | -113.8% | -122.5% | · |
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das + neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Quelle: SEC 10-Q eingereicht Jul 30, 2026